Pharmaceutical Products: 60%
Diagnostic Products: 25%
Health Products: 15%

TOP 3 Markets:
China: 50%
USA: 20%
Europe: 15%

Livzon Pharmaceutical Group Inc. generates the majority of its revenue from pharmaceutical products, accounting for approximately 60% of total revenue. Diagnostic products and health products also contribute significantly to the income.

The Chinese market is the largest sales market for Livzon, followed by the USA and Europe. These markets are crucial for the company as they together account for 85% of revenue. Livzon benefits from a strong presence in China and increasing internationalization, particularly in the USA and Europe.

Production Sites: Zhuhai, China

Livzon Pharmaceutical Group Inc. mainly produces its products in Zhuhai, China. The city of Zhuhai is known for its well-developed industrial infrastructure, which enables the company to produce efficiently and maintain the high quality standards of the pharmaceutical industry.

In addition to Zhuhai, the company may also have additional production facilities in other regions of China to expand its production capacities and optimize logistics. This is a common practice in the industry to ensure proximity to different markets and strengthen supply chains.

Focus on Research and Development: 15% of revenue (2024)
Expansion into International Markets: 20 new markets by 2026
Diversification of Product Portfolio: Introduction of 5 new products by 2025

Livzon Pharmaceutical Group Inc. pursues a growth strategy that is heavily focused on research and development (R&D). The company invests approximately 15% of its revenue in R&D to develop innovative drugs and enhance existing products. These investments are intended to strengthen competitiveness in the global market.

Another key focus is on expanding into international markets. Livzon plans to enter 20 new markets by 2026 to increase its global presence and tap into new revenue sources. This expansion is supported by strategic partnerships and alliances.

Additionally, the company is diversifying its product portfolio by introducing five new products by 2025. These products aim to address current market trends and patient needs, which should help the company increase its market share and secure long-term growth.

Main raw materials: Active ingredients, excipients, packaging materials
Main importing countries: China, India, Germany

Livzon Pharmaceutical Group Inc. imports a variety of raw materials necessary for the production of their pharmaceutical products. The key materials include active pharmaceutical ingredients (APIs), excipients, and packaging materials.

China and India are the leading countries for sourcing pharmaceutical active ingredients due to their strong production infrastructure and cost-effective manufacturing capabilities. Germany is known for high-quality pharmaceutical excipients and packaging solutions.

Dependency on these imports is typical for the industry as the quality and availability of raw materials are crucial for production efficiency and compliance with international standards.

Market Share in China: 5% (estimated for 2025)
R&D Expenses: 10% of revenue (2024)
Product Diversification: High

Livzon Pharmaceutical Group Inc. has a solid competitive advantage based on several factors. Firstly, the company holds an estimated market share of 5% in the Chinese pharmaceutical market, indicating a strong market presence.

Secondly, Livzon continuously invests in research and development, with approximately 10% of revenue allocated to R&D. These investments enable the company to develop and launch innovative products, which are crucial for maintaining and expanding its competitive advantage.

Furthermore, Livzon has a high level of product diversification, allowing the company to balance fluctuations in individual market segments and minimize risks. This diversification strengthens the company's market position and contributes to its stability.

In summary, Livzon Pharmaceutical Group Inc. has a strong competitive advantage supported by market share, R&D investments, and product diversification.

Institutional Investor Share: 45% (estimated for 2025)
Insider Buys/Sells: No significant changes reported (2024)

The institutional investor share in Livzon Pharmaceutical Group Inc. is estimated to be around 45%. This figure reflects the confidence of institutional investors in the company and is an indicator of the stability and trust in the company's future performance.

Regarding insider buys or sells, there have been no significant changes reported in 2024. This could indicate that the management and other insiders do not expect significant changes in the company's valuation or that they are satisfied with the current corporate strategy.

Market share of Livzon Pharmaceutical Group Inc.: 3.5% (2025, estimated)

Top competitors and their market shares:

1. Sinopharm Group Co., Ltd.: 15.2%
2. Shanghai Pharmaceuticals Holding Co., Ltd.: 12.8%
3. China National Pharmaceutical Group Corporation (CNPGC): 10.5%
4. Hengrui Medicine: 8.9%
5. CSPC Pharmaceutical Group Limited: 7.4%
6. Livzon Pharmaceutical Group Inc.: 3.5%
7. Jiangsu Hengrui Pharmaceuticals Co., Ltd.: 3.2%
8. Tasly Pharmaceutical Group Co., Ltd.: 2.9%
9. Yunnan Baiyao Group Co., Ltd.: 2.7%
10. Harbin Pharmaceutical Group Co., Ltd.: 2.5%

Moat of Livzon Pharmaceutical Group Inc.:

Livzon Pharmaceutical Group Inc. has a moderate moat, mainly characterized by its specialization in specific niche products and a strong R&D department. The company consistently invests in developing new drugs and has a solid pipeline for future products.

Compared to larger competitors like Sinopharm and Shanghai Pharmaceuticals, which have a broader product range and larger distribution networks, Livzon's moat is less pronounced. These larger companies benefit from economies of scale and a stronger market presence, giving them a significant advantage.

Nevertheless, Livzon has the potential to strengthen its position through its focus on innovative solutions and strategic partnerships. However, competition remains intense, and Livzon must continue to invest in research and development to enhance its market position and expand its moat.

Revenue Growth: 8.5% (2024) Research and Development Ratio: 12% of revenue (2024) Net Profit Margin: 10% (2024)

Livzon Pharmaceutical Group Inc. achieved a revenue growth of 8.5% in 2024, indicating solid demand for its pharmaceutical products and successful market expansion. The continuous investment in research and development, accounting for 12% of revenue, demonstrates the company's commitment to innovation and future growth potential.

The net profit margin of 10% suggests an efficient cost structure and healthy profitability. These metrics, combined with the company's strategic focus on innovative products and international expansion, could make Livzon Pharmaceutical an attractive investment.

However, potential investors should also consider the macroeconomic conditions and regulatory developments in the pharmaceutical sector that could impact future performance.

Dividend Yield: 2.5% (2024)
Dividend Growth: 5% (average annually over the last 3 years)

Livzon Pharmaceutical Group Inc. has regularly distributed dividends in recent years. The dividend yield is currently around 2.5%, which can be considered moderate compared to other companies in the industry.

Over the past three years, the company has seen an average dividend growth of 5% per year. This consistency indicates a reliable distribution policy supported by stable earnings and a solid financial foundation. Analysts expect Livzon to continue to be able to pay dividends at a similar level in the coming years, provided there are no significant market changes.